Previously reported Phase 1 Part 3B interim data demonstrated a statistically significant 68.1% placebo-adjusted reduction in liver fat, alongside 13.5% placebo-adjusted weight loss and improvements in glycemic control.
Read more: bit.ly/4iOmgvC $MTVA
74
MetaVia expects to report full Phase 1 Parts 3A and 3B data in the first quarter of 2027 and is preparing a 48-week Phase 2 study of DA-1726 in MetALD and ALD, targeted to begin in the second half of 2027.
Read more: bit.ly/4iOmgvC $MTVA
74
MetaVia President and CEO Hyung Heon Kim comments on the encouraging preliminary safety and tolerability observations seen in the Phase 1 Part 3A study of DA-1726, and the Company's preparations to advance DA-1726 into Phase 2 development: bit.ly/4iOmgvC $MTVA
44
MetaVia today announced that the last patient has completed the final study visit for its Phase 1 clinical trial evaluating DA-1726, a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist. Read more about the study: bit.ly/4iOmgvC $MTVA
56
"Given our focus on liver-related metabolic disease, we are particularly encouraged that DA-1726 increased both gene expression and protein levels of hepatic Fgf21, a key hormone in the regulation of lipid and carbohydrate metabolism," said H.H. Kim, CEO. bit.ly/4kjL1AU $MTVA
54
DA-1726 demonstrated statistically significant increases in liver and circulating FGF21 expression, alongside increased expression of genes associated with thermogenesis and energy expenditure. Read more: bit.ly/4kjL1AU #OW2026 $MTVA
72
MetaVia today announced positive preclinical head-to-head data comparing DA-1726, a novel GLP-1/glucagon dual agonist, with retatrutide, a triple GLP-1R/GIPR/GCGR agonist. Read more about the findings presented at ObesityWeek® 2026: bit.ly/4kjL1AU #OW2026 $MTVA
83
MetaVia CEO Hyung Heon Kim comments on the clinical progress of DA-1726, highlighting encouraging interim Phase 1 results demonstrating significant reductions in liver fat, body weight and uric acid, and the program’s planned advancement into Phase 2 development for MetALD and ALD in the second half of 2027.
Read more: bit.ly/4iGkeO1 $MTVA
1
18
MetaVia today announced financial results for the third quarter ended September 30, 2026, and provided a corporate strategic update. For third quarter 2026 highlights and anticipated clinical milestones, visit: bit.ly/4iGkeO1 $MTVA
17
“These additional findings further strengthen the metabolic profile emerging for DA-1726 and provide another encouraging signal as we advance its development in liver-related cardiometabolic diseases,” said Hyung Heon Kim, President and $MTVA CEO: bit.ly/4jdoc0D
25
